BACKGROUND: Proangiogenic cell therapy based on administration of bone marrow-derived mononuclear cells (BMCs) or endothelial progenitor cells (EPCs) is now under investigation in humans for the treatment of ischemic diseases. However, mechanisms leading to the beneficial effects of BMCs and EPCs remain unclear. METHODS AND RESULTS: BMC- and CD34+-derived progenitor cells interacted with ischemic femoral arteries through SDF-1 and CXCR4 signaling and released nitric oxide (NO) via an endothelial nitric oxide synthase (eNOS)-dependent pathway. BMC-induced NO production promoted a marked vasodilation and disrupted vascular endothelial-cadherin/beta-catenin complexes, leading to increased vascular permeability. NO-dependent vasodilation and hyperpermeability were critical for BMC infiltration in ischemic tissues and their proangiogenic potential in a model of hindlimb ischemia in mice. CONCLUSIONS: Our results propose a new concept that proangiogenic progenitor cell activity does not rely only on their ability to differentiate into endothelial cells but rather on their capacity to modulate the function of preexisting vessels.
BACKGROUND: Proangiogenic cell therapy based on administration of bone marrow-derived mononuclear cells (BMCs) or endothelial progenitor cells (EPCs) is now under investigation in humans for the treatment of ischemic diseases. However, mechanisms leading to the beneficial effects of BMCs and EPCs remain unclear. METHODS AND RESULTS:BMC- and CD34+-derived progenitor cells interacted with ischemic femoral arteries through SDF-1 and CXCR4 signaling and released nitric oxide (NO) via an endothelial nitric oxide synthase (eNOS)-dependent pathway. BMC-induced NO production promoted a marked vasodilation and disrupted vascular endothelial-cadherin/beta-catenin complexes, leading to increased vascular permeability. NO-dependent vasodilation and hyperpermeability were critical for BMC infiltration in ischemic tissues and their proangiogenic potential in a model of hindlimb ischemia in mice. CONCLUSIONS: Our results propose a new concept that proangiogenic progenitor cell activity does not rely only on their ability to differentiate into endothelial cells but rather on their capacity to modulate the function of preexisting vessels.
Authors: Mervin C Yoder; Laura E Mead; Daniel Prater; Theresa R Krier; Karim N Mroueh; Fang Li; Rachel Krasich; Constance J Temm; Josef T Prchal; David A Ingram Journal: Blood Date: 2006-10-19 Impact factor: 22.113
Authors: T J Grazia; R J Plenter; H M Lepper; F Victorino; S D Miyamoto; J T Crossno; B A Pietra; R G Gill; M R Zamora Journal: Am J Transplant Date: 2010-11-29 Impact factor: 8.086
Authors: Isabelle Brunet; Emma Gordon; Jinah Han; Brunella Cristofaro; Dong Broqueres-You; Chun Liu; Karine Bouvrée; Jiasheng Zhang; Raquel del Toro; Thomas Mathivet; Bruno Larrivée; Julia Jagu; Laurence Pibouin-Fragner; Luc Pardanaud; Maria J C Machado; Timothy E Kennedy; Zhen Zhuang; Michael Simons; Bernard I Levy; Marc Tessier-Lavigne; Almut Grenz; Holger Eltzschig; Anne Eichmann Journal: J Clin Invest Date: 2014-06-17 Impact factor: 14.808
Authors: Karina Ckless; Anniek Lampert; Jessica Reiss; David Kasahara; Matthew E Poynter; Charles G Irvin; Lennart K A Lundblad; Ryan Norton; Albert van der Vliet; Yvonne M W Janssen-Heininger Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Marc Benderitter; Fabio Caviggioli; Alain Chapel; Robert P Coppes; Chandan Guha; Marco Klinger; Olivier Malard; Fiona Stewart; Radia Tamarat; Peter van Luijk; Charles L Limoli Journal: Antioxid Redox Signal Date: 2014-02-03 Impact factor: 8.401